Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis
Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Amer M. Zeidan(Yale Cancer Center), Gail J. Roboz(Cornell University), Maximilian Stahl(Harvard University), Hetty E. Carraway(Cleveland Clinic), Hayley Hawkins(Vanderbilt University Medical Center), David A. Sallman(Moffitt Cancer Center), Amy E. DeZern(Johns Hopkins University), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Tariq Kewan(Yale University), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Maria L. Amaya(University of Colorado Denver), Jessica M. Stempel(University of New Haven), Zhuoer Xie(Mayo Clinic), Ondřej Bláha(Yale University), Michael R. Savona(Vanderbilt University), Mikkael A. Sekeres(University of Miami), Namrata S. Chandhok(Sylvester Comprehensive Cancer Center), Carmelo Gurnari(University of Rome Tor Vergata), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Benjamin Rolles(Brigham and Women's Hospital), Rahul Ramaswamy(Vanderbilt University Medical Center), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Christine M. McMahon(Albert Einstein College of Medicine), Pinkal Desai(NewYork–Presbyterian Hospital), Jaroslaw P. Maciejewski(Cleveland Clinic), Justin Grenet(Cornell University), Matteo Giovanni Della Porta(Humanitas University), Rory M. Shallis(Smilow Cancer Hospital), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Amyah C. Harris(Dana-Farber Cancer Institute), Andrew M. Brunner(Harvard University), Najla H. Al Ali(Moffitt Cancer Center), Rami S. Komrokji(Moffitt Cancer Center)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k